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ABSTRACT 
AIMS: To evaluate the growing evidence base of mobile phone applications for the 
selfmanagement of type 1 and 2 diabetes mellitus. Then, to investigate the impact of app functions 
as moderating effects, including the impact of health care professional (HCP) feedback incorporated 
in the apps.   
MATERIALS AND METHODS: A systematic review with metaanalysis, metaregression and 
GRADE of the evidence. Relevant randomized controlled trials that were published between 1 
January 1996 and 1 May 2017 and reported either HbA1c or severe hypoglycemic episodes as 
outcomes were searched in five databases: Medline, CINAHL, Cochrane Library, Web of Science, 
and Embase.  
RESULTS: 1550 participants from 21 studies were included in the review. For type 1 diabetes, a 
significant 0.49% reduction in HbA1c was seen (95%CI 0.04 to 0.94; I2=84%), with unexplained 
heterogeneity and a low GRADE of evidence. For type 2 diabetes, using diabetes apps was 
associated with a mean reduction of 0.57% in HbA1c (95%CI 0.32 to 0.82, I2=77%). The results had 
severe heterogeneity that was explained by the frequency of HCP feedback. In studies with: no HCP 
feedback, a mean reduction of 0.24% (95% CI 0.02 to 0.49; I2=0%); low frequency, mean reduction 
of 0.33% (95% CI 0.07 to 0.59; I2=47%); and high frequency a mean reduction of 1.12% (95%CI 
0.91 to 1.32; I2=0%), with high GRADE of evidence.  
No evidence was found of excess severe hypoglycemic episodes associated with diabetes apps 
(seven studies).   
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CONCLUSIONS: There is evidence that diabetes apps improve glycemic control in type 1 diabetes 
patients. A reduction of 0.57% in HbA1c was found in type 2 diabetes patients. However, HCP 
involvement is critical functionality to achieve clinical effectiveness. A costeffectiveness study is 
needed to evaluate whether diabetes apps should be used routinely.   
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INTRODUCTION 
In the past three decades, the number of people with diabetes worldwide has risen from 153 million 
in 1980 [1] to 382 million in 2013 [2], and is expected to rise to 592 million by 2035 [2]. The high 
prevalence of diabetes gives rise to the increased global healthcare costs on diabetes and, more 
importantly, its complications. The estimated health expenditure on diabetes worldwide increased 
from 548 billion US dollars in 2013 to over 612 billion US dollars in 2014 [3], imposing a huge 
economic burden to healthcare systems.  
Nevertheless, there are overwhelming evidence that intensive glycated hemoglobin (HbA1c) control 
can significantly reduce the risk of diabetes complications [4, 5]. But nowadays, the percentage of 
diabetes patients achieving the recommended HbA1c target remains low [6, 7]. The importance of 
patients selfmanagement in achieving HbA1c l vel of below 6.5% is wellrecognized. Traditional 
diabetes selfmanagement education (DSME) that aimed to improve diabetes selfmanagement has 
shown to be associated with approximately 0.5% reductions in HbA1c [8, 9]. However, the wide 
implementation of these selfmanagement strategies is unrealistic in current overburdened 
healthcare systems, as these strategies are historically resourceintensive and requires time from 
healthcare professionals (HCPs) and patients.   
Diabetes mobile phone applications (diabetes apps) is a newly emerging technology for diabetes 
selfmanagement. Due to its ubiquitous, cheap, interactive, and dynamic health promotion [10], 
diabetes apps may provide effective diabetes selfcare by supporting diabetes patients in all the 
selfcare behaviors and overcome the weakness of the current selfmanagement strategies at the 
meantime. Our previous systematic review demonstrated that diabetes apps are effective in 
Page 5 of 51
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
controlling HbA1c in type 2 diabetes patients [10], this conclusion was supported by three later 
systematic reviews [1113]. However, there is still uncertainty on whether diabetes apps are effective 
in the selfmanagement of type 1 diabetes, and which aspects of the apps are associated with better 
self management. There is current debate to what extent the effect of diabetes apps on HbA1c should 
be attributed to Health Care Professionals (HCP) [14].  
The primary objective of this study is to determine the effectiveness and safety of the apps, and 
secondary objectives are to establish which features are likely mediating effects.    
MATERIALS AND METHODS 
Literature searching, selection criteria and data extraction 
This study is an update of a systematic review following a prespecified protocol and follows the 
PRISMA statement and checklist (PROSPERO reg. no. CRD42017067774). We searched relevant 
peerreviewed studies published between June 1st, 2015 and May 1st, 2017 in five electronic 
databases: Medline, CINAHL, Cochrane Library, Web of Science, and Embase. The following terms 
and medical subject headings (MeSH) were used: mobile, mHealth, cell phones, cellular phone, 
smartphone, app, mobile applications, iphone, phone, diabetes mellitus, T2DM, T1DM, IDDM, 
NIDDM, DM, T1D, T2D, or MODY (Supplementary Table 1). The references of the included 
studies were hand searched to identify additional articles. 
The inclusion and exclusion criteria used were: ≥18 years old participants with type 1 or type 2 
diabetes; the studies adopted randomized controlled trials (RCTs) design and reported HbA1c or 
severe hypoglycemic episodes as an outcome; the control group in the study received usual care 
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without any telehealth interventions. We define severe hypoglycemic episodes as any hypoglycemic 
episodes that require thirdparty assistance. For data extraction, participant demographics, study 
design considerations, and context were extracted from each included study (Supplementary tables 2 
and 3). Corresponding authors were contacted to provide missing data, and where necessary, we used 
statistical methods to impute missing data [15, 16]. Literature searching, screening (including 
rescreening of previous search results for hypoglycemic episodes) and data extraction were 
conducted by two reviewers independently (CH and QX). Any disagreements were resolved by 
discussion with a third reviewer (JYL).   
Risk of bias (RoB) assessment  
The nine Cochrane RoB domains were categorized as low risk of bias, high risk of bias, or unclear 
of each study [17]. Risk of bias will be independently evaluated by two authors (CH and SD) and 
any discrepancies in bias coding were resolved by a third reviewer (BC). Studies were classified with 
a high RoB if they determined as having a high RoB for both blinding and incomplete outcome data 
domains. If all domains were a low RoB the study was described with a low RoB, and unclear if a 
combination of low and unclear domains.  
Data analysis and synthesis  
The primary outcome is HbA1c, and secondary outcome is severe hypoglycemic episodes. For the 
primary outcome, we used the inverse variance random effects model [18] to pool mean differences 
(MD) in HbA1c changes from baseline or postintervention HbA1c for type 1 and type 2 diabetes 
studies separately [18]. The I2 statistic was used to assess and quantify heterogeneity. When 
substantial heterogeneity was found (I2>50%), we explored the source of heterogeneity using 
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subgroup analysis and metaregression. For the secondary outcome, DerSimonian & Laird 
randomeffects model [18] was used to carry out the pooling of risk ratios (RR) with the estimate of 
heterogeneity being taken from the MantelHaenszel model [19].  
For cluster randomized controlled trial, effect size abstracted from an analysis that properly accounts 
for the cluster design is preferred [17]. Otherwise, an effective sample size will be used instead: 
Neffective= N/(1+(m-1)*ICC) (m: number of observations per cluster, ICC: intracluster correlation 
coefficient) [20], where parameter ICC was calculated from one of the included cluster randomized 
controlled studies [21]. All the statistical analyses were conducted using STATA (version 14.1) and 
Comprehensive MetaAnalysis (version 3). 
Subgroup analyses and meta-regression
Subgroup analyses by HCP intensity were carried out for both type 1 and type 2 diabetes studies to 
explain heterogeneity. Randomeffects metaregressions were further carried out for type 2 diabetes 
studies to explore the factors that may influence the efficacy of apps on glycemic control. We 
applied a modification to the variance of the estimated coefficients as suggested by Knapp and 
Hartung [22] and used the residual maximum likelihood (REML) method to estimate betweenstudy 
variance [23]. Univariable metaregression analyses by length of the study follow up, baseline HbA1c
levels, and ages of the participants were carried out first. We then conducted multivariable 
metaregression analyses to investigate what functions of the apps could influence HbA1c control 
after adjusting for the predictors that found to be statistically significant (p<0.05) in the univariable 
metaregressions. In the multivariable metaregression analyses, Tau2 was used to reflect 
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betweenstudy variance while I2residual was calculated to reflect residual variation due to 
heterogeneity. 
Sensitivity analyses and publication bias 
For the primary outcome we removed studies with: a high RoB; had missing data imputation; and 
studies conducted on mixed participants. When 10 or more studies were pooled, we used funnel plot 
to visually inspect publication bias.  
RESULTS
The literature search in five databases resulted in 4467 records, plus 5211 records identified on June 
2015. Thirtytwo manuscripts (21 studies) were included and 116 were excluded (Figure 1).  In the 
21 included studies [21, 2443], three studies enrolled both type 1 and type 2 diabetes patients, of 
these, two studies provided additional data and could be included in both type 1 and type 2 syntheses 
[32, 34], and the third study included predominantly type 2 diabetes patients (>90%) so was 
classified as type 2 [30]. In total, 1550 participants were included in the metaanalysis, of which 516 
were type 1 diabetes patients (average 35.3 ys old and 18.4 years of diabetes duration) and 1034 
were type 2 diabetes patients (average 55.2 years old and 9.5 years of diabetes duration) 
(Supplementary Table 2). The median followup period is 6 months (range 39 months) and 6 
months (range1.512 months) in type 1 and type 2 diabetes studies respectively. 
INCLUDE FIGURE 1 HERE 
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One type 1 diabetes study [42] and three type 2 diabetes studies [30, 31, 33] were at high RoB, while 
the risk of bias in the remaining studies was unclear (Supplementary Figure 1 and 2). Studies with a 
high RoB were largely due to: blinding; use of fixed permutedblock randomization (in openlabel 
trials); and high loss to follow up. 
A total of 19 diabetes apps were assessed in 21 included studies, of which, four apps were assessed 
in type 1 diabetes patients, 12 in type 2 diabetes patients and three in both type 1 and type 2 diabetes 
patients. We examined diabetes apps in the following nine domains of functionality: selfmonitoring 
tasks supported, data entry method, CHO/insulin bolus calculator, medication adjustment support, 
realtime personalized feedback (automated feedback provided by apps), structured display (display 
of blood glucose and other selfmonitoring data), HCP feedback, frequency of HCP feedback and 
other functionalities (Supplementary Table 3). We further categorized HCP feedback into three 
groups according to the frequency of HCP feedback: no HCP feedback (did not support or provide 
additional HCP feedback in the intervention group), low frequency HCP feedback (when necessary 
or less than or equal to once per month) and high frequency HCP feedback (more than once per 
month). Among type 1 diabetes apps, two apps aimed to help patients with insulin bolus calculation 
and the others were designed to improve selfmanagement by providing automated feedback or HCP 
feedback. None of type 1 diabetes apps supported realtime personalized feedback while wireless 
selfmonitoring data transmission was supported in only one apps. As for HCP feedback, it was 
provided in four apps, with the frequency ranging from once per week to once per month. On the 
contrary, majority of the type 2 diabetes apps were designed to support diabetes selfmanagement by 
providing personalized feedback on selfmonitoring data (blood glucose, physical activity et al.). 
Besides, wireless data transmission and realtime personalized feedback was supported in 
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approximately half of the apps. In terms of HCP feedback, four studies of diabetes apps had no HCP 
feedback. In the remaining 12 studies of diabetes apps, seven provided low frequency HCP feedback 
and five had high frequency HCP feedback. 
For primary outcome, seven studies on type 1 diabetes reported controversial results. After pooling, 
we found a mean reduction of 0.49% in HbA1c that favored the intervention (95% CI 0.04 to 0.94; 
P=0.03, Figure 2), (hereafter, the reported values always refer to absolute reduction in HbA1c), but 
exhibited considerable heterogeneity (I2 = 84%), which was partially explained by HCP feedback 
(Figure 2). The differences between the subgroups were insignificant (P=0.26). We conducted two 
sensitivity analyses. Removing one study with incomplete data [43] reported an insignificant 
reduction of 0.49% (95% CI 0.04 to 1.01). When one study with high RoB was removed [42], the 
mean reduction decreased to 0.35% (95% CI 0.11 to 0.81). The level of evidence by GRADE is low, 
downgraded due to blinding and imprecision.   
For type 2 diabetes, five studies reported statistically significant HbA1c reduction that favored the 
apps, nine studies found improvements in HbA1c but did not reach statistical significance, and two 
studies did not find any difference between the intervention and control groups. The pooled results 
indicated that compared with control, using diabetes apps was associated with a mean reduction of 
0.57% in HbA1c (95% CI 0.32 to 0.82; P < 0.01; Figure 3). Although these results exhibited 
significant heterogeneity (I2 = 77%), it was explained by the HCP intensity (Figure 3). Studies with 
no HCP feedback reported a mean reduction of 0.24% (95% CI 0.02 to 0.49), whereas studies 
included low and high frequency HCP feedback had mean reductions of 0.33% (95% CI 0.07 to 0.59) 
and 1.12% (0.91 to 1.32) respectively. The level of evidence by GRADE for diabetes apps is high, 
based on downgrading for blinding but upgrading for doseresponse.    
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For type 2 diabetes studies, three sensitivity analyses were conducted. Removing studies [30, 31, 33] 
with high risk of bias resulted in a mean reduction of 0.56% (95% CI 0.28 to 0.84). Exclusion of one 
study [30] that enrolled both type 1 and 2 patients reported a mean reduction of 0.57% (95% CI 0.30 
to 0.83). Finally, we removed one study with incomplete data [29] and the mean reduction did not 
change distinctly (0.53%, 95% CI 0.28 to 0.79). There is no indication of publication bias in 
Supplemental Figure 3.  
Although seven studies looked at severe hypoglycemic episodes [27, 28, 31, 36, 3941], only one 
type 1 diabetes study [41] reported a total of four episodes of severe hypoglycemic in the 
intervention and control groups (one in the intervention group and three in the control group). 
Therefore, pooling of severe hypoglycemic episodes was not conducted as planned. 
INCLUDE FIGURE 2 AND FIGURE 3 HERE 
Meta-regression analysis 
In the univariable metaregression analyses (Supplementary Figure 4), we found a statistically 
significant relationship between baseline HbA1c levels and effect size (P=0.02), suggesting the 
reduction in HbA1c was likely to increase with the baseline HbA1c levels. We also found that mean 
ages of the participants was inversely associated with effect size, indicating studies with younger 
participants may report larger effect size compared with trials with older participants (P=0.03). As 
for study length, its relationship to effect size was not statistically significant (P=0.82). 
Based on the results from single covariate metaregressions, we conducted series of multivariable 
metaregressions that adjusted for ages and baseline HbA1c values respectively. After adjusting for 
baseline HbA1c levels, we found a significant doseresponse relationship between HCP feedback and 
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effect size (P=0.02, Tau2=0.04, I2-res=37.22%, Supplementary Figure 5). This doseresponse 
relationship remained to be significant when we adjusted for mean ages of the participants (P=0.01, 
Tau2=0.05, I2-res=45.85%). As for the other functionalities of the diabetes apps, their effect on 
glycemic control was insignificant in both models (Supplementary Figure 6). 
DISCUSSION
This systematic review updated the body of evidence of diabetes apps to improve glycemic control in 
the selfmanagement of diabetes. A total of 21 studies were included in this review, of which 8 
studies were newly identified. For type 1 diabetes, a statistically significant reduction in HbA1c that 
favored the use of diabetes apps is reported for the first time. The results reaffirmed that apps for 
type 2 diabetes help with selfmanagement, but also demonstrated a HCP doseresponse with HbA1c. 
The magnitude of the effect in the diabetes apps group with a highest level of HCP was higher than 
that in our previous metaanalysis [10].  
Compared with three recent similar metaanalysis [1113], the strengthens of our metaanalysis are 
most updated searching of the literatures, strict following of a registered protocol, exclusion of 
studies conducted on participants aged <18 years old and studies that used other kinds of electronic 
devices. Furthermore, out analysis were conducted separately for type 1 and type 2 diabetes patients. 
One of the novel findings of our review is that we reported a statistically significant reduction in 
HbA1c among type 1 diabetes patients for the first time. Although previous reviews also revealed that 
diabetes apps that incorporated HCP feedback may be more effective, their conclusions are based on 
subgroup analysis and omit the potential effect of confounders. In our review, we used multivariable 
Page 13 of 51
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
metaregression analyses to adjust for potential confounders and revealed a significant doseresponse 
relationship between HCP feedback and HbA1c reduction, which makes our conclusion more robust.  
Nevertheless, our study has some limitations. Firstly, for the purpose of obtaining detailed 
information on the diabetes apps, we restricted the review to published articles, which may 
introduced publication bias. Due to the characteristics of the diabetes apps interventions, 
doubleblind study design is not applicable, which raised the issue of high risk of ascertainment bias 
in all the included studies. Meanwhile, the assessment of risk of bias of included studies was 
inadequate for some domains, due to the lack of important information in some of the studies. 
Fourthly, the covariates included in the metaregression models were study level data rather than 
patient level data, making our findings vulnerable to the ecological fallacy. Finally, because of 
insufficient numbers of studies, we were not able to investigate interactions between different 
functionalities of the apps. 
Although the results in type 2 diabetes were associated with significant heterogeneity, it was 
significantly decreased after we stratified the studies by HCP intensity. The residual heterogeneity is 
acceptable for complex interventions like diabetes apps. The results from univariable 
metaregressions suggested that baseline HbA1c levels was a significant mediator for the effect of 
diabetes apps. The positive association between baseline HbA1c levels and reductions in HbA1c is 
anticipated and accordant with findings in other diabetes researches [44, 45], as patients with higher 
baseline HbA1c levels generally have poorer glycemic control and are therefore more likely to 
benefit from interventions. The inverse linear relationship between mean ages of the participants and 
reductions in HbA1c agrees with our previous hypothesis that younger patients were more likely to 
benefit from the use of diabetes apps [10]. Since it has been reported that older patients were less 
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interested in the use of diabetes apps [46], it is plausible that diabetes apps is less effective among 
older patients. However, there is no convincing external evidence supporting such hypothesis [47], 
and future researches need to investigate into this relationship more deeply. Our results revealed no 
significant association between followup duration and this finding is also supported by four studies, 
in which the HbA1c reductions in the intervention groups kept stable at different followup visits [31, 
33, 34, 38]. However, whether the effect of diabetes apps can sustain for a longer period of time (>1 
year) is still largely unknown.  
Results from multivariable metaregressions statistically confirmed the hypothesis that the effect of 
diabetes apps in glycemic control is largely attributed to the effect of HCPs [12]. Although diabetes 
apps is projected to increase patients selfefficacy and promote behavior change through features 
like reminder and realtime personalized feedback [14, 48], the effect of sole use of diabetes apps is 
likely to be small. There are two possible explanations for this finding. First, vast majority of the 
apps were not based on behavior change theory and had little impact on influencing lifestyle choice 
of the patients. Second, due to the limitations of technology, automated feedback can only provide 
limited support on selfmanagement. Compared with diabetes apps with low frequency HCP 
feedback, those with high frequency feedback have significantly larger effect size. We speculate this 
difference is not only the result of different HCP intensity, but also the result of different types of 
HCP feedback. Among the four studies with high HCP intensity, all of them provided medication 
adjustment support. Whereas in the eight studies with low HCO intensity, medication adjustment 
support from HCPs was included in less than half of the studies. Our speculation is consistent with 
the findings from previous metaanalysis investigating other diabetes telemedicine interventions and 
diabetes quality improvement strategies [45, 49]. Therefore, we believe it is medication adjustments 
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support that plays a crucial role in the effect of HCP feedback. Based on these results, we postulate 
two main mechanisms behind the effects of diabetes apps on HbA1c reduction (Supplementary Figure 
7): (a) HCP feedback provide patients with medication adjustments and lifestyle modifications 
support (b) Selfmonitoring using apps facilitates the HCP feedback.         
For studies on type 1 diabetes, although we found a statistically significant reduction of 0.49%, the 
result was not robust and had some heterogeneity. Compared with the very low level of evidence we 
reported previously [10], the current level of evidence was rated up to low by GRADE, meaning 
future research is likely to change the estimate. It is notable that only one type 1 diabetes apps 
supported automatic data uploading functionality, therefore, we encourage more diabetes apps that 
include this functionality to be designed for type 1 diabetes patients.  
Although there is some indication that the use of diabetes apps is associated with no excess severe 
hypoglycemia episodes, current evidence for the safety of diabetes apps is scarce. Future studies of 
diabetes apps should pay more attentions to the safety issues, especially for apps with bolus 
calculator functionality [50]. 
In recent years, the enthusiasm for diabetes apps is increasing with the worldwide smartphone usage 
rate. The purpose of our findings is not to dampen such enthusiasm, but to highlight the gaps in 
current diabetes apps and suggest future researches in this area. The populationwide implementation 
of diabetes apps need the support from both clinicians and payers. For clinicians, their primary 
consideration is not only the clinical effect of using diabetes apps for diabetes patients, but more 
importantly whether the time spent on adapting the technology and sending feedback justify the 
perceived benefit [51]. Hence, for future researches, we appeal that the intensity and types of HCP 
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feedback should always be reported with enough detail, so that clinicians can have a more 
comprehensive look at the study results. In order to fulfil HCPs needs, future diabetes apps need to 
reduce dependencies in HCP feedback. We suggest that future diabetes should be underpinned by 
behavioral principles and diabetes selfmanagement guidelines and incorporate gamification 
elements [52] and social medial function [46]. As for payers, costeffectiveness of the intervention is 
their primary concern. Future investigators should consider conducting a comprehensive economic 
evaluation that takes into account both the direct and indirect cost of the diabetes apps. Meanwhile, 
investigators need to pay more attentions to evaluating the safety of diabetes apps. Furthermore, the 
longterm effects (>1 year) of diabetes apps are still unknown and need to be investigated in more 
pragmatic observational studies.  
Conclusion 
This systematic review and metaregression reveals a robust 0.57% reduction in HbA1c for diabetes 
apps compared with usual care in type 2 diabetes. However, this reduction in HbA1c is largely 
dependent on the effect of health care professionals, which highlights the importance of 
comprehensive economic evaluation and developing more effective apps in the future. As for type 1 
diabetes, we found a statistically significant reduction in HbA1c that supported the use of diabetes 
apps, but the level of evidence was low. There is some indication that using diabetes apps will not 
increase the risk of severe hypoglycemic episodes. But the evidence is limited and more studies are 
needed.  
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Legends to figures 
Figure 1—PRISMA flowchart of included studies 
Figure 2: Pooled type 1 diabetes studies of HbA1c comparison of apps vs. control (subgroup by 
HCP feedback) 
Figure 3: Pooled type 2 diabetes studies of HbA1c comparison of apps vs. control (subgroup by 
HCP feedback) 
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Figure 1 
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Figure 2 
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Figure 3 
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Supplementary Figure 1. ‘Risk of bias’ graph: review authors’ judgements about 
each risk of bias item presented as percentages across all included studies. 
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Supplementary Figure 2. ‘Risk of bias’ summary: review authors’ judgements 
about each risk of bias item for each included study.
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Supplementary Figure 3: Funnel plot of type 2 diabetes studies 
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Supplementary Figure 4: Univariate meta-regressions of mean ages, mean 
baseline HbA1c levels and length of follow-up. 
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Supplementary Figure 5: Multivariate meta-regressions of HCP feedback after 
adjustment for mean ages or baseline HbA1c levels 
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Supplementary Figure 6: Multivariate meta-regressions of the other functions of 
diabetes apps after adjustment for mean ages or baseline HbA1c levels    
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Supplementary Figure 7: Postulated mechanisms behind the effects of diabetes 
apps 
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Supplementary Table 1: Detailed search strategy used in each database. 
Data sources Databases Search Strategy 
OVID 
Medline: Ovid MEDLINE(R) 1996 to Present with Daily Update, Ovid 
MEDLINE(R) Epub Ahead of Print, Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations 
(mobile.af. or mHealth.af. or exp Cell Phones/ or cellular phone*.af. or exp Smartphone/ or app.af. or apps.af. or exp Mobile 
Applications/ or iphone*.af. or phone*.af.) and (exp Diabetes Mellitus/ or diabet*.af. or T2DM.af. or T1DM.af. or IDDM.af. or 
NIDDM.af. or DM.af. or T1D.af. or T2D.af. or MODY.af.) 
EMBASE 
EBSCO CINAHL Plus 
((TX mobile) OR (TX mHealth) OR (TX cellphone*) OR (MM "Cellular Phone+") OR (MM "Smartphone+") OR (TX app) OR (TX 
apps) OR (MM "Mobile Applications")  OR (TX iPhone*) OR (TX phone*)) AND ((MM "Diabetes Mellitus+") OR (TX diabet*) OR 
(TX T2DM) OR (TX T1DM) OR (TX IDDM) OR (TX NIDDM) OR (TX DM) OR (TX T1D) OR (TX T2D) OR (TX MODY)) 
Web of Science Web of Science 
(TS=(mobile OR mHealth OR cellphone* OR cellular phone* OR smartphone* OR app OR apps OR mobile application* OR iphone* 
OR phone*) OR TI=(mobile OR mHealth OR cellphone* OR cellular phone* OR smartphone* OR app OR apps OR mobile 
application* OR iphone* OR phone*)) AND (TS=(diabetes mellitus OR diabet* OR T2DM OR T1DM OR IDDM OR NIDDM OR 
DM OR T1D OR T2D OR MODY) OR TI=(diabetes mellitus OR diabet* OR T2DM OR T1DM OR IDDM OR NIDDM OR DM OR 
T1D OR T2D OR MODY)); Timespan=2015-2017; Search language=Auto   
Cochrane The Cochrane Library 
Search all text: mobile OR mHealth OR cellular phone* OR app OR apps OR iphone* OR phone* (#1) 
MeSH descriptor: [Cell Phones] explode all trees (#2) 
MeSH descriptor: [Smartphone] explode all trees (#3) 
MeSH descriptor: [Mobile applications] explode all trees (#4) 
Search all text: diabet* OR T2DM OR T1DM OR IDDM OR NIDDM OR DM OR T1D OR T2D (#5) 
MeSH descriptor: [Diabetes Mellitus] explode all trees (#6) 
(#1 or #2 or #3 or #4) and (#5 or #6) Publication Year from 2015 to 2017 
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Name (year) Studydesign
Length
(mths)
Number of
participants
randomised
Dropped out
Number of
participants
in the
analysis
Imputation
methods Country Setting Intervention group(s)
Control
group Inclusion criteria Exclusion criteria Study outcomes
Age (years,
mean and SD)
Gender (male
%)
Duration of
diabetes
(years, mean
and SD)
Treatment regimen Ethnic groups Baseline Post-intervention
Change from
baseline
Severe
Hypoglycem
ia (n)
I: 27
I: 4 (1
missing
value)
I: 23 I:62.3 (6.5) I: 54 I: 6.86 (1.56) I: -0.37 (0.83)
C: 29 C: 5 C: 24 C:61.5 (9.1) C: 54 C: 7.09 (1.51) C: 0.00 (0.84)
FTA: 51
FTA-HC: 50
FTA: 11
FTA-HC: 10
FTA: 39
FTA-HC: 40
FTA: 58.6 (11.8)
FTA-HC: 57.4
(12.1)
FAT: 67
FAT-HC: 50
FTA: diet 7% oral
agents 44% injections
20% oral and injecton
30%; FTA-HC: diet 4%
oral agents 57%
injections 15% oral
and injecton 23%
FTA: 8.1 (1.25)
FTA-HC:
8.1(1.05)
FTA: 7.8 (1.033)
FTA-HC: 8.0
(1.44)
FTA: -0.31
(1.11)
FTA-HC: -0.15
(1.36)
C: 50 C: 9 C: 41 C: 55.9 (12.2) C: 60
C: diet 11% oral
agents 42% injections
8% oral and injecton
40%
C: 8.4(1.25) C: 8.2 (1.33) C: -0.16 (1.08)
I: 15 I: 15 I:55.3 (8.7) I: 40% I: 6.4 (0.6) I: -0.1 (0.3)
C: 15 C: 15 C:56.7 (10.6) C: 33.3% C: 6.5 (0.7) C: 0.3 (1.0)
I: 27 I: 3 I: 27 I:57.1 (10.2) I: 74 I: 9.6 (7.0)
I: no medication 26%,
oral 48%, noninsulin
injection 15%, injection
and oral 11%
I: 7.1 (1.0) I: 6.7 (0.7)
C: 27 C: 2 C: 27 C: 57.4 (9.4) C: 78 C: 8.5 (8.0)
C: no medication 22%,
oral 74%, noninsulin
injection 0%, injection
and oral 4%
C: 7.0 (0.9) C: 7.1 (1.1)
I: 8 I: 1 I: 7 I:56 (8) I: 71 I: 3.0 (0.6-4.7) I: 8.0 (1.0) I: 6.9 (0.7) I: No severe(1 mild hypo)
C: 9
C: 3 (1
missing
value)
C: 6 C:60 (13) C: 71 C: 2.3 (0.4-8.0) C: 8.2 (1.2) C: 7.5 (1.4) None
I: 62 I: 5 I: 57 I:57.0 (9.1) I: 64.8 I: 6.0 (5.4) I: 7.6 (0.9) I: 7.1 (0.8)
C: 61 C: 7 C: 54 C:59.4 (8.4) C: 52.6 C: 7.2 (6.0) C: 7.4 (0.9) C: 7.6 (1.0)
I: 15 I: 2 I: 13 I: 31 I: 7.61
I: oral 23%, insulin
31%, injectible non-
insulin 46%
I: 9.51 I: 7.48 I: -2.03*
C: 15 C: 2 C: 13 C: 38 C: 11
I: oral 54%, insulin
31%, injectible non-
insulin 8%
C: 9.05 C: 8.37 C: -0.68*
I: 72 I: 40 I: 32 I:60 (12) I: 13.3 (8.6)
I: diet 5%, insulin 26%,
OHA 47%, OHA and
insulin 22%
I: 7.9 (1.5) I: 7.76#
C: 65 C: 10 C: 55 C:57 (13) C: 11.7 (8.0)
C: diet 5%, insulin
25%, OHA 56%, OHA
and insulin 11%
C: 8.1 (1.6) D: 8.4#
N/AFinland Communityhealth center
Patients in the intervention
group used Monica to
monitor their BP, body
weight, physical activity, and
BG (for some patients).
Standard medical
care NA
NA
Utilization of the system,
HbA1c, BMI, blood pressure,
physical activity, diabetes self-
care and self-efficacy
NA
FTA: patients used the
FewTouch to monitor their
food habits, BG, and physical
activity.
FTA-HC: Group 1 +
teleconsulting provided by
nurses for the first four
months (5 times in total with
a mean duration of 20 mins).
N/AOrsama et al. (2013)(24)
N/A12 NA Norway Primary care
N/A
RCT 10 NA
N/AN/A3 NANA
N/A
N/A
General
practices
Hospital and
community
health center
N/A
NACommunityhealth center
Hospital
Supplementary Table 2: Baseline characteristics of the included studies and participants
Type 2 diabetes studies
Oral medication: 100%
N/A
NA
Waki et al. (2014)
(26) RCT 3
Lat
observation
carried
forward
Japan
Patients
continued their
self-care regimen
Standard diabetes
self-managemen
Patients used the app to
monitor their BG, exercise,
and weight.
(i) age≥18 years; (ii) type 2 diabetes
diagnosed by a health professional at least 1
year prior and confirmed by other clinical
laboratory data (Fasting Plasma Glucose>126
mg dL-1 and/or 2-hour 75-g oral glucose
tolerance test OGTT>200 mg dL-1; (iii)
controlled by either diet or oral medications for
at least 3 months; (iv) BMI >25; (v) no
exogenous insulin use; (vi) a glycosylated
haemoglobin (HbA1c)<8% reflecting fair to
good glycemic control; and (vi) serum
creatinine<1.5 mg dL-1
N/A
Patients in the intervention
group used the DialBetics to
monitor their BG, BP, body
weight, and activity.
have any severe complications— serum
creatinine below 1.5 mg/dl, or proliferative
retinopathy—and had to be able to exercise.
NA
Primary: HbA1c
Other: FBS, BP, BMI, LDL-
C,HDL-C, and triglyceride,
DialBetics’s usability,
participants' satisfaction
Holmen et al. (2014)
(25) RCT
Faridi et al. (2008)
(21)
Cluster
RCT (2
clinics)
known diagnosis of type 2 diabetes, elevated
HbA1c ( >6.5%) or currently using oral
diabetes medication, age range of 30–70
years combined with HbA1c >6.5%, systolic
blood pressure >140mm Hg, or diastolic
blood pressure >90mm Hg,
NA
Usual care
according to
clinical guidelines
expected poor study compliance (e.g.,
information technology illiteracy or
reluctance to perform self-monitoring),
pregnancy, patients with life
expectancy of less than 1 year,
patients with major elective surgery
within the past 6 months or planned
for the next 6 months, patients with
psychiatric disorders (e.g.,
depression), or alcohol or narcotics
abuse
Primary: HbA1c and systolic
and diastolic blood pressure
Secondary: body weight
Other: Patient acceptance and
usability and usefulness of the
feedback system
Yoo et al. (2009)
(28) RCT 3 NA Korea Usual out-patienttreatment
Patients in the intervention
group used the app to
monitor their BG, BP,
exercise, and body weight.
diagnosis of both Type 2 diabetes and
hypertension at least 1 year previously by a
physician; (ii) HbA1c 6.5–10.0%; (iii) blood
pressure > 130 ⁄ 80 mmHg; and (iv) body
mass index (BMI) ≥ 23.0 kg ⁄m2 (overweight
according to Asia-Pacific criteria)
Patients in the intervention
group used the app to
monitor their BG.
≥35 years old with type 2 diabetes of at least 3
months’ duration and were taking oral
glucoselowering medication, ast routinely
measured HbA1c ≥64 mmol/mol (8.0%) and
<97 mmol/mol (11.0%) with no subsequent
records of increase in oral glucose-lowering
medication
Nagrebetsky et al.
(2013) (27) RCT 6 NA UK
Usual care and
supportive
lifestyle
intervention
USA
aged ≥18 years, had an HbA1c level ≥7.1%
(54.1 mmol/mol), and were capable of
completing questionnaires in the Norwegian
language, be cognitively able to participate
and to use the system and devices provided
NA
Primary: HbA1c
Secondary: self-management
and health-related quality of life,
depressive
symptoms, and lifestyle
changes
N/A
N/A
were unable to follow the trial protocol
due to physical, cognitive, or social
limitations; were prescribed insulin; or
required addition of insulin to
treatment regimen, visual impairment,
pregnancy or breast feeding, and
limited life expectancy or other
comorbid conditions making tight
blood glucose control inappropriate
HbA1c and changes of oral
glucose-lowering medication White: 100%
N/AN/A
Community
endocrinology
and
community
primary care
practice
Hospital
a physical inability to self-monitor
blood glucose, pregnancy, severe
lifethreatening or terminal illness or an
inability to provide written informed
consent
Primary: HbA1c NA
Patients received
care from the
diabetes center
Patients used the app to
monitor their BG.
Ambulant patients aged over 18 years with
diabetes
Patients
continued usual
standards of care
NA
not reported
in both
groups
(i) severe diabetic complications; (ii)
liver dysfunction with aspartate
aminotransferase or alanine
aminotransferase > 2.5 times the
reference level, or renal dysfunction
(serum creatinine > 132 lmol ⁄ l); (iii)
medical history of congestive heart
failure, angina pectoris, myocardial
infarction, or stroke based on a
physician’s diagnosis; (iv) pregnancy
or lactation; or (v) othermedical
problems that could affect study
results or trial participation
Weight; BMI; waist
circumference; BP; right
baPWV; left baPWV; HbA1c;
fasting glucose; HOMA-IR;
lipids; triglyceride; adiponectin;
hsCRP; interleukin-6
NA
African
American: 62%
White: 38%
N/A
Patients used the app to
monitor their BG, medication
dosage, and food intake.
Quinn et al. (2008)
(29) RCT 3
Istepanian et al.
(2009) (30)$ RCT 9
Caucasian:
34%
African-
Caribbean:
31%
Indo-Asian:
31%
Other: 4%
NA UK
NA USA
18–70 years old who had a diagnosis of type
2 diabetes for at least 6 months. Study
patients were required to have an A1c  7.5%
and to have been on a stable diabetes
therapeutic regimen for 3 months prior to
study enrollment.
NA
Primary: HbA1c
Secondary: HCPs’ adherence
to prescribing guidelines; HCPs
’ adoption of the technology
Others: Change in medication;
diabetes self-care; self-reported
control issues
51.0 (11.03)
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CO: 38
CPP: 33
CPDS: 80
CO: 15
CPP: 11
CPDS: 18
CO: 23
CPP: 22
CPDS: 62
CO: 52.8 (8.0)
CPP: 53.7 (8.2)
CPDS: 52 (8.0)
CO: 52.2
CPP: 45.5
CPDS: 50
CO: 7.7 (5.6)
CPP: 6.8 (4.9)
CPDS: 8.2 (5.3)
CO: 9.3 (1.8)
CPP: 9.0 (1.8)
CPDS: 9.9 (2.1)
CO: 7.7 (1.0)
CPP: 7.9 (1.4
CPDS: 7.9 (1.7)
CO: -1.6 (1.50)&
CPP: -1.2
(1.47)&
CPDS:-1.9
(1.58)&
C: 62 C: 6 C: 56 C:53.2 (8.4) C: 50 C: 9.0 (7.0) C: 9.2 (1.7) C: 8.5 (1.8) C: -0.7 (1.49)&
I: 40+ I: 0+ I: 40+ I: 55.0 (13.1) I: 54 I: 6.65 (5.14)
I: oral: 26%, insulin:
40%, insulin and oral
34%
I: 9.86 (2.38) I: 7.91 (1.58) I:-1.83 (0.95)+
C: 42+ C: 0+ C: 42+ C: 53.5 (12.4) C: 60 C: 6.63 (5.06)
C: oral: 26%, insulin:
46%, insulin and oral
28%
C: 9.76 (2.51) C: 8.97(2.08) C: -0.65 (0.32)+
I: 67 I: 19 I: 48 I: 53.1 (10.9) I: 35 I: 8.69 (1.32) I: 7.88 (1.17) I: -0.815 (1.05)
C: 64 C: 15 C: 49 C: 53.3 (11.9) C: 20 C: 8.89 (1.30) C: 8.13(1.27) C: -0.759 (1.39)
I: 41+ I: 4+ I: 37+ I: 58.2 (13.6) I: 68.9 I: 16.5 (8.5)
I: insulin 22.2%, oral
and insulin 77.8% I: 8.78 (1.56)
+ I: 8.29 (1.39)+ I: -0.53 (1.45)+
C: 30+ C: 4+ C: 26+ C: 55.8 (13.8) C: 42.7 C: 16.9 (6.8)
C: insulin 31.4%, oral
and insulin 71.4% C: 8.66 (1.56)
+ C: 8.91(1.16)+ C: 0.12 (1.15)+
I: 10 I: 0 I: 10 I: 44.2 (6.66) I: 6.2 (3.82) I: 8.76 (0.76) I: 7.85 (0.70) I: -0.91 (0.63)
C: 10 C: 0 C: 10 C: 46.1 (6.44) C: 5.7 (3.2) C: 8.5 (1.45) C: 8.68 (1.54) C: 0.18 (0.35)
I: 33 I: 4 I: 29 I: 10.09 (2.06) I: 8.25 (1.18) I: -1.59 (1.62)
C: 33 C: 3 C: 30 C: 9.75 (1.37) C: 8.28 (1.07) C: -1.48 (0.97)
I: 32 I: 2 I: 30 I: 59.9 (5.31) I: 56.6 I: 6.78 (1.10) I: 6.75 (0.95) 0.04 (0.52)
C: 30 C: 0 C: 30 C: 59.0 (8.09) C: 63.3 C: 6.84 (0.98) C: 6.78 (0.92) 0.01 (0.36)
I: 44 I: 3 I: 41 I: 48.8 (9.0) I: 82 I: 10 (median) I: orals only 50%,insulin 50% I: 9.4 (1.2) I: 7.9 (1.1) I: -1.5 (1.1)
C: 46 C: 7 C: 39 C: 48.0 (9.5) C: 58.7 C: 8.8 (median) C: orals only 55.1%,insulin 46.3% C: 9.1 (1.1) C: 8.2 (1.5) C: -0.8 (1.6)
I: 63 I: 8 I: 63 I: 38.4 (10.3) I: 46.0 I: 16.2 (10.0)
I: basal-bolus regimen
with insulin analogs:
100%
I: 8.4 (0.79)* I: 7.9 (0.79)* I: -0.49 (0.87)*
C: 64 C: 7 C: 64 C: 34.3 (10.0) C: 49.1 C: 15.0 (8.4)
C: basal-bolus
regimen with insulin
analogs: 100%
C: 8.5 (0.80)* C: 8.1 (0.80)* C: -0.48 (0.88)*
treatment with NPH insulin or soluble
regular insulin, continuous
subcutaneous insulin infusion, insulin
regimens other than basal:bolus,
eating disorders (based on the
physician’s judgment), pregnancy/
lactation, inability to send or receive
SMSs, inability or unwillingness to
give informed consent, or any other
disease or condition that could
interfere with the compliance with the
protocol or the study completion
Primary: HbA1c
Secondary: FBG; glucose
variability; daily doses of
insulin;  hypoglycaemic
episodes; body weight; lipids;
blood pressure
Other: Quality of life; patient
satisfaction
N/A
IRR: 1.08
(grade 1)
0.14 (grade
2)
Bee et al. (2016)
(36)
Kleinman et al.
(2017) (38)
Type 1 diabetes studies
I: Intervention; C: Control
# P=0.06 for between groups difference
$ Studies conducted on mixed populations of type 1 and type 2 diabetes patients (majority of which are type 2 )
& Means and SDs from mixed-effects model
+ For type 2 diabetes patients only (data were additionally provided by corresponding authors)
* Pooled SD=2.08 (imputed using Prognostic Method) (15)
Rossi et al.  (2013)
(39) RCT 6
Unstructure
d correlation Italy
Diabetes
clinics
Patients in the intervention
group used DID to calculate
the most appropriate dose to
be injected at each meal
Standard
educational
approach based
on CHO counting
diagnosis of T1DM, 18 years of age, no
previous education on CHO counting, HbA1c
levels ‡7.5%, treatment with a basal-bolus
regimen with insulin analogs, SMBG
measurements at least three times a day, and
adequate familiarity in the use of mobile
phones according to the physician judgment
Zhou et al. (2016)
(32)$
RCT 3 NA China Hospital
NA
Black: 39%
White: 53%
Other: 8%
None in both
groups
CO: Patients used the app to
monitor their BG, diet, and
medication
CPP: CO + a web-portal
allow HCPs to access
unanalysed patient data
CPDS: CO + a web-portal
allow HCPs to access
analysed patient data
Chinese:
100% NA
The intervention group
installed Welltang on their
smart phones and used for
diabetes self-management
Patients received
usual care once a
month
be able to use a smart phone, have no severe
complications such as end-phase diabetic
nephropathy or proliferative diabetic
retinopathy, and be able to exercise
Quinn et al. (2011)
(31) ClusterRCT 12
Linear
mixed effect
model
USA
Patients were
provided care as
usual
Medicare or Medicaid beneficiaries;
Uninsured; Insulin pump users; Not
currently managed by study
physicians; Pregnant; Active
substance, alcohol, or drug abuser
(sober ,1 year); Psychotic or
schizophrenic under active care;
Severe hearing or visual impairment;
or No Internet or e-mail access.
Primary: HbA1c
Secondary: Depressive
symptoms; patient-reported
symptoms associated with
diabetes; blood pressure; lipids;
Hypoglycemic events;
hospitalization; emergency
room visits
N/A
NA
Participants allocated to the
intervention group were
provided with the MTH
equipment (BG meter, BP
monitor, mobile-phone, and
Bluetooth cradle) and training
Primary: HbA1c
Secondary: weight, BMI, waist
circumference, Changes in
psychometric assessments
Wayne et al. (2015)
(33) RCT 6 NA Canada
Primary care
clinics NA NA
Black
Caribbean:
40%
Caucasian:
27%
Hispanic: 9%
West Indian:
6%
Other: 18%
Baron et al. (2017)
(34)$
RCT 9 NA UK Diabetes clinic Standard care
age 18 or above, poorly controlled type 1 or
type 2 diabetes (HbA1c57.5%)31–33 with the
latest HbA1c collected within the last 12
months, taking insulin, and fluency and
literacy in English.
Previous experience using MTH,
regular extended travels (53 weeks)
outside the UK, home visits by a
district nurse for BG monitoring and/or
insulin administration, a diagnosis of
kidney failure or sickle cell disease,
pregnancy, and dexterity/visual
problems compromising the use of a
mobile-phone
Primary: HbA1c
Secondary: BP, daily insulin
dose, number of DOAs
attended
Other outcomes: health-related
quality of life, symptoms of
depression and anxiety
NA NA NA
Patients were given the
SAED system and were
trained to operate and run the
blood glucose device
and to transmit the
measurements
Standard care T2D patients of both genders with an agegroup between 20–65 years
Alotaibi et al. (2016)
(35) RCT 6 NA
Kingdom of
Saudi
Arabia
Hospital
Primary: HbA1c
Second: BG, LDL-C, Weight,
BP, hypoglycemic events,
satisfaction, diabetes
knowledge, self-care behaviors.
White: 25%
Black: 33%
Asian: 36%
Other: 6%
Primary care
practices
Physician diagnosis of type 2 diabetes for $6
months; Glycated hemoglobin $7.5% within 3
months; Age 18–64 years.
Oral: 100% NA
no episodes
of severe
hypoglycemi
a (one
confirmed
hypoglycemi
c event: I:
27.3%
C: 21.2%)
53.3 (7.4) 12 (8)
NAN/A HbA1c and the Diabetesknowledge test
Hospital
Patients entered FBG
readings into the app daily;
the app responded with a
suggested insulin dose
Patients in the
control group
used paper
logbooks and
written
instructions
Insulin-naive T2DMpatientswith suboptimal
glycemic control (HbA1c ≥7.5% [58
mmol/mol]) despite use of two or more oral
glucose-lowering drugs
Hypoglycemia unawareness; Severe
renal impairment (i.e., eGFR <30
ml/min); Corticosteroid use Serious
disease with life expectancy <1 year
Pregnancy; Patients with labile
medical conditions that would
predispose them to poor insulin
control (e.g., frequent or recurrent
infections); Patients with
psychological and social issues that
would prevent continuous injection of
insulin and monitoring of blood
glucose (e.g., major depressive
disorder, homelessness)
Primary: HbA1c
Secondary: hypoglycemic
episodes, Treatment
satisfaction, fasting plasma
glucose,
66.70%
NA
Patients used the app to track
key metrics and
communicate with health
coach at any time in the 24-
hour cycle
Patients received
health coach
support without
access to the app
diagnosed with T2DM, if they had an HbA1c
≥ 7.3% (56.3 mmol/mol) measured within 1
month of consent, and if they were under 70
years of age
N/A
Kardas et al. (2016)
(37) RCT 1.5 NA Poland Primary care
Patients were equipped with
COMMODITY12 system,
composed of smart phone,
and wirelessly connected
sensors
Standard care
age 18–65 years, diabetes type 2 diagnosed
≥6 months prior to the study, currently in the
maintenance phase of treatment (of which at
least a part consisted of the use of metformin,
with a daily dose of ≥500 mg), and self-
committed ability to use the cell phone and
the sensors
inter allia, the need to rely on the other
persons with drug taking
Primary: system operability and
whole
trial feasibility
Secondary: HbA1c, plasma
glucose levels, arterial blood
pressure, patient adherence,
health-related
quality of life
NA NA NANA
RCT 6 NA Singapore
Control
participants were
instructed to
manage their
diabetes as usual
Willing to participate and be randomized; Able
to speak and read either English, Hindi,
Gujarati, or Tamil; Diagnosed with type 2
diabetes for > 6 months; Age 18–65 inclusive,
any gender; A1c of 7.5–12.5% (58–113
mmol/mol), inclusive; On stable diabetes
therapy for >3 months; Own an Android
smartphone; Have not previously used the
Gather app
Currently using an insulin pump,
continuous glucose monitor, or
glucocorticoids; Pregnant or planning
to become pregnant in the next 12
months; Received or are planning to
receive an organ transplant; Recent
major surgery or planning to have
major surgery; Active substance,
alcohol, or drug abuse (abstinent <1
year); Severe hearing or visual
impairment; Significant psychiatric
illness, renal disease, hepatic
disease, or other disease that
impaired ability to complete the study
or follow study protocol
Primary: change in A1c from
baseline to 6 months
Secondary: change in A1c from
baseline to 3 months, change in
body mass index, waist
circumference, blood pressure,
fasting BG, lipids, measures of
medication adherence, BG
testing, communication with
doctors, treatment satisfaction,
diabetes self-care activities,
diabetes distress, self-efficacy,
and diabetes knowledge
NA NARCT 6 NA India Diabetes clinic
Intervention was use of
Gather Health, an m-Health
diabetes management
platform
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I: 67 I: 9 I: 67 I: 35.4 (9.5) I: 44.8% I: 17.1 (10.3)
I: Short-acting and/or
long-acting analogs
80.6%, Continuous
subcutaneous insulin
infusion 19.4%
I: 8.2 (0.8) I: 7.8 I: -0.4 (0.9)
I: 2 (mild
hypoglycemi
a)
C: 63 C: 2 C: 63 C: 36.1 (9.4) C: 41.0% C: 15.8 (10.7)
C: Short-acting and/or
long-acting analogs
80.9%, Continuous
subcutaneous insulin
infusion 19.1%
C: 8.4 (0.7) C: 7.9 C: -0.5 (1.0)
C: 2 (mild
hypoglycemi
a)
G2: 60
G3: 59
G2: 4
G3: 2
G2: 56
G3: 57
G2: 32.9 (11.7)
G3: 31.6 (12.5)
G2: 38.3
G3: 37.3
G2: 17.6 (8.9)
G3: 14.7 (9.1)
G2: Insulin pump
36.7%
G3: Insulin pump
36.7%
G2: 9.12 (1.01)
G3: 8.14 (1.15)
G2: 8.63 (1.07)
G3: 8.41 (1.04)
G2: -0.49 (0.89)
G3: -0.73 (0.84)
Severe
episodes
G2: 3
G3: 1
C: 61 C: 1 C: 60 C: 36.8 (14.1) C: 34.4 C: 16.9 (10.5) C: Insulin pump 36.1% C: 8.92 (0.91) C: 9.10 (1.16) C: 0.18 (0.83)
Severe
episodes
C: 3
I: 36 I: 11 I: 25 I: 36.0 (10.7) I: 52.8 I: 19.7 (9.6) I: Insulin pump 38.9% I: 9.08 (1.18) I: 7.80 (0.75) I: -1.10 (0.74) NA
C: 36 C: 8 C: 28 C: 34.4 (10.3) C: 25 C: 18.2 (9.8) C: Insulin pumo 36.1% C: 8.47 (0.86) C: 8.58 (1.16) C: 0.07 (0.99) NA
I: 10& I: 0& I: 10& I: -2.24 (1.05)&
C: 8& C: 0& C: 8& C: -1.52 (1.14)&
I: 31 I: 1 I: 31 I: 33 I: 65 I: 18 (17)
I: continuous
subcutaneous insulin
infusion 65%, multiple
daily injections 35%
 I: 8.01 (1.65) I: 7.88+ I: -0.13#
C: 32 C: 0 C: 32 C: 35 C: 63 C: 15 (14)
C: continuous
subcutaneous insulin
infusion 66%, multiple
daily injections 34%
C:7.55 (1.28) C: 7.91+ C: 0.36#
I: 4& I: 1& I: 3& I: 11.88 (3.16)& I: 11.47(3.38)& I: 0 (1.44)&
C: 6& C: 1& C: 5& C: 9.99 (2.14)& C: 9.48(1.98)& C: -0.41 (2.37)&
I: Intervention; C: Control
* SDs were calculated from SEs or 95% CIs
# Pooled SD=2.27 (imputed using Prognostic Method)
& For type 1 diabetes patients only (data were additionally provided by corresponding authors)
$ Studies conducted on mixed populations of type 1 and type 2 diabetes patients
+ Means were imputed from median,q1 and q3 (16)
previous experience using MTH,
regular extended travels (53 weeks)
outside the UK, home visits by a
district nurse for BG monitoring and/or
insulin administration, a diagnosis of
kidney failure or sickle cell disease,
pregnancy, and dexterity/visual
problems compromising the use of a
mobile-phone
Primary: HbA1c
Secondary: BP, daily insulin
dose, number of DOAs
attended
Other outcomes: health-related
quality of life, symptoms of
depression and anxiety
NA NA NA NA NA NA
Baron et al. (2016)
(34)$
RCT 9 NA UK Diabetes clinic
Participants allocated to the
intervention group were
provided with the MTH
equipment (BG meter, BP
monitor, mobile-phone, and
Bluetooth cradle) and training
Standard care
age 18 or above, poorly controlled type 1 or
type 2 diabetes (HbA1c57.5%)31–33 with the
latest HbA1c collected within the last 12
months, taking insulin, and fluency and
literacy in English.
NA NA
Kirwan et al. (2013)
(42) RCT
RCT 3 Not reported Netherland Hospital
Patients in the intervention
group were asked to use the
DBEES application and a
personal web portal linked to
the DBEES application
Patients kept their
paper diary
Drion et al. (2015)
(43)
owned a smartphone (other than a
BlackBerry) and were familiar with its use;
over 18 years old, had T1DM, and were
treated with multiple daily injections (MDI),
continuous subcutaneous insulin infusion
(CSII), or continuous intraperitoneal insulin
infusion (CIPII)
had used a diabetes application in the
3 months prior to their visit, did not
have internet or email access, or were
unable to read Dutch
Primary: QOL
Secondary: diabetes-related
distress, HbA1c, daily
frequency of SMBG, usability of
DBEES system
N/A
Diabetes
Australia in
New South
Wales and
Queensland
Patients in the intervention
group used Glucose Buddy
to monitor their BG, insulin
dosage, medications, diet,
and physical activity.
Patients
continued usual
care
(1) aged 18-65 years, (2) diagnosed with type
1 diabetes >6 months, (3) HbA1c >7.5%, (4)
treated with multiple daily injections or insulin
pump, and (5) own a smartphone (iPhone)
NA
pregnant or already using a
smartphone application to self-
manage their diabetes
Primary: HbA1c
Secondary: Diabetes-related
self-efficacy; self-care activities;
quality of life
N/A
Zhou et al. (2016)
(32)$
RCT 3 NA China Hospital
The intervention group
installed Welltang on their
smart phones and used for
diabetes self-management
Patients received
usual care once a
month
be able to use a smart phone, have no severe
complications such as end-phase diabetic
nephropathy or proliferative diabetic
retinopathy, and be able to exercise
N/A
Primary: HbA1c
Second: BG, LDL-C, Weight,
BP, hypoglycemic events,
satisfaction, diabetes
knowledge, self-care behaviors.
NA NA NA NA Chinese:100% NA
9 NA Australia
participation in a diabetes educational
program within 3 months before the
study or a clinical condition requiring
the patient to receive follow-up more
frequently than the quarterly visits
scheduled
Primary: HbA1c
Secondary: patients reaching
the HbA1c target of below
7.5%; SMPG frequency; quality
of life; Patient satisfaction
Other: Major and minor
hypoglycaemia episodes
N/A
Rossi et al.  (2010)
(40) RCT 6
Last
observation
carried
forward
Italy,
England
and Spain
Diabetes
outpatient
clinics
Patients in the intervention
group used DID to calculate
the matching insulin bolus at
each meal
Standard
carbohydrate
counting
education
diagnosis of type 1 diabetes, age  18 years,
no previous education on carbohydrate
counting, and treatment with multiple daily
injections of shortacting and long-acting
insulin analogs or with continuous
subcutaneous insulin infusion; patients
practiced self-monitoring of blood glucose at
least three times a day; patients were
adequate familiarity in the use of mobile
phones, according to the physician judgment,
and possession of a personal mobile phone
card
Charpentier et al.
(2011) (41) RCT 6
Last
observation
carried
forward
France Hospital
Group 2: Patients used
Diabeo to calculate bolus and
received two face-to-face
follow-up visits.
Group 3: Patients used
Diabeo to calculate bolus and
received teleconsultations by
telephone call every two
weeks.
Patients kept their
paper logbook
and attended two
follow-up visits
Participants were over 18 years old, had type
1 diabetes for at least 1 year, and had been
treated with a basal bolus insulin regimen for
at least 6 months, either with MDI or with a
pump. HbA1c values during the year before
and at entry of the study were at least 8.0%
being treated with NPH insulin or
soluble regular insulin, had an eating
disorder, were pregnant, were unable
to send or receive short text
messages, were unable or unwilling to
give informed consent, or had any
other disease or condition that may
interfere with compliance with the
protocol or completion of the study
Primary: HbA1c
Secondary: FBG, body weight,
lipid   profile, BP
Other: safety related problems,
time spent in educational
activities, quality of life, patient
treatment satisfaction
N/A
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Name (year) App used inthe study Self-monitoring tasks Data entry method
CHO/insulin
bolus
calculator
Medication
adjustment
support
Real-time
personalized
feedback
Structured
display HCP feedback
Freq. of HCP
feedback
Categories of freq. of
HCP feedback Other functionalities
1. Real-time graph display reflecting the uploaded data in relation to individual target
value generated by app.
2. Automatically generated, theory-based, health promotion-rich information,
motivation, and behaviour skills feedback messages, linked to patients’ remote reports
of their health parameters.
3. Study nurses scanned through the status of all intervention patients each week and
contacted patients if warranted by their remote data reports.
4. A web portal (Medinet) enabled participants to view their uploaded data.
FewTouch NO YES
Type 2 diabetes studies
Supplementary Table 3: Characteristics of the apps in the included studies
Feedback received
Orsama et al.
(2013) (24) Monica
BG, BP, body weight, and
physical activity (pedometer)
NO
1. Real-time feedback from the app on how the individually set goals were met within
the defined period.
2. Motivational feedback through symbols such as smiling faces and colour codes in
the app.
3. Patients can also access related tips and look up words and concepts related to
their diseases.
All data were manually
imputed YES
Holmen et al.
(2014) (25) NO
NA
1. Real-time, automated, graphical and texts feedback and reminders based on
patient-specific data.
2 .Upon receipt of newly submitted patient data, the Confidant server software will
generate and send one or more feedback messages directly to the patient’s cell phone.
3. A web-based portal for patients and clinicians to view measurement data and prior
messages received from the system.
NICHE BG, exercise (pedometer) andweight
BG and weight data
were automatically
transmitted (indirectly);
pedometer counts
were manually entered
NO NO NOYES
NA
Personal goal setting
system, general
diabetes education
system
Food habits registration, BG, and
physical activity
BG data were
automatically
transferred to the app;
activity data and food
habits were entered
manually
NO
NO NA YES YES
When necessary (study
nurses scanned
through patients' status
each week)
Waki et al. (2014)
(26)
YES
YES
Faridi et al. (2008)
(21)
YES
When necessary (no
readings were defined
as abnormal, a health
care provider’s time
was not required)
The database
triggered alerts for
missed or late
readings (reminder)
1. Data were automatically evaluated following the Japan Diabetes Society (JDS)
guideline’s targeted values, DialBetics determined if each reading satisfies guideline
requirements, then immediately sent those results to each patient’s smartphone.
2. Readings defined as abnormal were reported to a doctor as “Dr Call,” meaning a
physician will check the data and interact with the patient if necessary.
3. Voice input was converted to text and matched with text in the DialBetics database;
advice on lifestyle modification, matched to the patient’s input about food and
exercise, was sent back to each patient immediately after the patient’s input.
4. Patients’ photos of meals were sent to the server; the nutritional value of those
meals was calculated by dieticians, then sent back to each patient.
5. Patients can view their measurement data as well as graphic outputs of their
measurements with diet and exercise history.
DiaBetics
BG, BP, body weight and
pedometer counts,
voice/text messages about meals
and exercise,  photos of meals
BG,BP, body weight
and pedometer data
were transmitted
automatically to the
app;
meals and exercise
were input by
voice/text message or
photos
NO  NA YES
NA
1. Real-time automated SMS feedback of encouragement, reminders, and
recommendations according to the data input.
2. Participants received information via SMS three times a day regarding healthy diet
and exercise methods, along with general information about diabetes, hypertension
and obesity.
3. A web-based portal for physicians to view patient data and send individualized
recommendations to patients when needed.
Ubiquitous
Chronic
Disease Care
BG, BP, exercise, and body
weight
BG data were
automatically
transmitted to the app;
BP and weight data
were manually entered
NO
YES YES Monthly NA
1. Real-time graphical feedback on glucose levels.
2. BG reading were also monitored by research nursing twice a week via a web-based
portal, and support and encourage patients using standardized text messages and
telephone calls monthly.
3. Patients used the phone application to review their glucose levels every 3 weeks
and, if necessary, titrate their oral glucose-lowering medication.
t+Diabetes BG
BG data were
automatically
transmitted to the app
NO NO
YES
Yoo et al. (2009)
(28)
NA
Nagrebetsky et al.
(2013) (27)
NO NO YES When necessary
Not specified BG
When necessary (by
study team) plus
feedback from HCP
every four weeks
Quinn et al. (2011)
(31)
Average one phone call
per month plus
intermittently electronic
messages (from every
week to every 2-3
months )
BG, medication dosage and
carbohydrates intake
BG data were
automatically sent to
the app, other data
were manually input
NO NA
Automatically
transmitted to the app NO
BG, carbohydrates consumed,
diabetes medications taken, and
miscellaneous comments
regarding diabetes self-care
BG data were
automatically sent to
the app, other data
were manually input
NO NA NO YES
Diabetes
Manager
YES
NO
YES
NO YESDiabetesManager
Quinn et al. (2008)
(29)
Istepanian et al.
(2009) (30)$ YES
1. Real-time educational, behavioural and motivational feedback regarding patients
input data, trend of recent entered data and physicians’ medication instruction.
2. Patients and PCPs had access to a web-portal consisted of secure messaging
centre (for patient-provider communication), personal health record with additional
diabetes information, learning library and logbook to review historical data (analysed
data).
3. Diabetes educators intermittently reviewed patient data and communicated with
patients electronically or via phone (frequency: high risk level patents: at most 4 times
a month; others every 2-3 months).
Direct patients to test
BG at optimal times
(reminder)
1. Real-time feedback about the BG level related to the patient-specific target level and
was shown HCP-prescribed medication instruction.
2. If BG levels were above or below target levels, patients received real-time feedback
on how to correct the BG level.
3. Data were sent to server and analysed by automated algorithms and research team;
patients would receive positive feedback if no problems detected; if problems detected,
patients were given further feedback and education, or even referral if needed.
4. Suggestions of medical changes to patients (approved by HCP first).
5. HCPs were provided with logbook to review, attached with analysis of the patient
data and trend.
The mobile phone
alerted the patient
when a measurement
was due (reminder)
1. The research clinicians reviewed the recordings via a web-based application. Letters
were sent from the clinician to the patients and their general practitioners with details
of the amalgamated readings and treatment recommendations.
NO YES Low level contact
Low frequency
No HCP feedback
No HCP feedback
No HCP feedback
Low frequency
Low frequency
High frequency
Low frequency
High frequency
NA
Reminder
Learning library
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1. CHO/insulin bolus calculator: DID can automatically calculate the most appropriate
insulin dose on the basis of entered BG, food intake (CHO and calories) and current
insulin dose, and predefined carbohydrate-to-insulin ratio and the glycaemic correction
factor, together with other information already filled out in the DID (e.g., physical
activity, glycaemic target, insulin dose, and specific events).
2. All the recorded data were sent to the physician on average each 1–3 weeks. Any
new therapeutic and behavioural prescriptions were sent from the diabetes clinic
computer to the patient’s mobile phone.
1. CHO/insulin bolus calculator: DID can automatically calculate the most appropriate
insulin dose on the basis of entered BG, food intake (CHO and calories) and current
insulin dose, and predefined carbohydrate-to-insulin ratio and the glycaemic correction
factor, together with other information already filled out in the DID (e.g., physical
activity, glycaemic target, insulin dose, and specific events).
2. Data stored in the mobile phone are periodically sent to the personal computer of
the physician. Then, any new therapeutic and behavioural prescription can be sent
from the computer to the mobile phone.
1. Bolus calculators using validated algorithms, taking into account carbohydrate
intake, pre-meal blood glucose, and anticipated physical activity reported by the
patient.
2. Automatic algorithms for the adjustment of carbohydrate ratio and basal insulin or
pump basal rates when the postprandial or fasting plasma glucose levels are off target
3. Data transmission to medical staff computers to allow easy telemonitoring and
teleconsultations
Food exchange,
prevention of
compliance
Food exchange,
prevention of
compliance
plasma glucose
targets
Average 2 meesages
per week sent to the
physician
High frequency
Charpentier et al.
(2011) (41) Diabeo
BG, carbohydrate intake and
physical activity
Data were manually
entered YES YES NO NO NO NA No HCP feedback
Rossi et al.  (2010)
(40)
Diabetes
Interactive Diary
BG, dose of insulin injections,
food intake, physical activity, and
specific events
Data were manually
entered YES YES NO NO YES
Rossi et al.  (2013)
(39)
Diabetes
Interactive Diary
BG, food intake (CHO and
calories), dose of insulin, physical
activities, and specific events
Data were manually
entered YES YES NO NO YES
Every one to three
weeks; average 0.8
message exchanged
per week
High frequency
$ Studies conducted on mixed populations of type 1 and type 2 diabetes patients (majority of which are type 2 )
Type 1 diabetes studies
Bee et al. (2016)
(36)
Kleinman et al.
(2017) (38)
Welltang
Not specified
Baron et al. (2017)
(34)$
YES YESSAED
Wayne et al. (2015)
(33)
BG, carbohydrate intake,
medications, physical activity,
blood pressure, and weight/height
Data were manually
entered NO
YES YESNexJ HealthCoach+
BG, exercise, food intake,
weight/BMI and mood
Data were manually
entered NO
Zhou et al. (2016)
(32)$
NOYES
1. The medical staff monitored and reviewed the patient’s condition using the data
collected and stored in the database to plan and advice on the treatment.
2. Based on the blood glucose and HbA1c readings from the database, automated
feedback was securely transmitted in real-time to the patients’ smart phone.
3. SMS education program wherein the patients received weekly messages to keep
them informed about diabetes and other related information.
4. Real-time graphical feedback on patient reported data.
BG
BG data were
automatically
transmitted
NO YESAlotaibi et al. (2016)(35)
1. Colour-coded graphical feedback on the data recorded was automatically displayed
following each data transfer.
2. MTH nurses provided feedback on out-of-range clinical readings (as needed).
3. MTH nurses made six weekly educational calls to deliver diabetes education.
4. MTH nurses supported insulin titration.
Average 37
minutes/week of
interaction (39
minutes/week of
interaction in the
control group)
Reminder and health
library
YES
NO
NO
NA
Patient can send
messages to HCP at
any time, HCP
monitored and
reviewed patients'
condition and advice
on treatment
General diabetes
education system and
computerized alerts
and reminders
YES YES YES
1. Real-time graphical feedback on patient reported data.
2. The HC co-monitored the client’s mobile phone input and directed immediate
attention (on a 24-hour/day and 7-day/week basis) to episodes of desirable progress,
relapse, and resistance.
3. Patients could communicate with their health coach at any time in the 24-hour cycle
via secure messaging, scheduled phone contact, and/or during in-person meetings.
1. Real-time graphical feedback on glucose levels.
2. The study team provided feedback on the blood glucose levels of patients, their
target goals, and their individualized medication regimens based on the data they
entered once a week or every 2 weeks.
3. Readings outside threshold limits would automatically trigger a message to be sent
to patients and notify clinicians.
4. Patients received an electronic action plan as pre-visit summaries for physician
office visits once a month.
Every one to two
weeks; average 3-10
min of time spent ;
mean number of
contacts was 11 (once
every week)
General diabetes
education system;
alerts for missed
readings and a
diabetes forum
YES YES
BG Data were manuallyentered YES YES NO YES YES
When necessary
(hypoglycaemic
episodes)
When necessary plus
six weekly educational
calls
BG, BP, physical activity, insulin
dose and weight
BG and BP data were
automatically
transmitted, other data
were manually entered
NO
1. Patients in the intervention group entered FBG readings into the app daily; the app
responded with a suggested insulin dose
2. An administrative module where the research staff could remotely monitor glucose
readings submitted and flag issues to the endocrinologists.
3. Generates graphs from the daily readings, so patients can see their progress in
managing their diabetes.
Low frequency
Kardas et al. (2016)
(37)
NO NA NO
COMMODITY1
2
Gather Health BG, medication Data were manuallyentered
1. BG tests submitted out of standard ranges had automated question follow-up to
identify issues, and participants could message questions to providers. Each site’s
health coach regularly responded to patient questions and systemgenerated alerts.
2. Provider contact with participants outside the system was discouraged, except in
cases of high-risk glycemic data or technical troubleshooting.
3. Real-time graphical feedback on patient reported BG data.
1. Artificial Intelligence Layer (AIL) proved to produce alerts according to the relevant
algorithms for cases of hypo- and hyperglycaemia, tachy- and bradycardia cases, as
well as the supposed risk of the sleep apnoea. These alerts were presented in the
system, and made ready for use by clinicians.
2. The data are interpreted by personal agents that use expert biomedical knowledge
to derive important insights about the individual’s health status, which are then
presented in the form of active feedback to the patient directly from the device, or via
health professionals who assist in diagnosis, treatment and life management.
3. Real-time graphical feedback on patient reported data.
YES YES
sent  497 messages to
providers, and received
890 messages from
providers.
The app automatically
reminded participants
to complete tasks
each day (reminder)
BG, ECG, heart rhythm,
respiratory movements, activity,
weight, BP and adherence
Data were
automatically
transmitted
NO YES YES NO YES
Diabetes Pal
When necessary
(hypo- and
hyperglycaemic
episodes)
N/ALow frequency
High frequency
High frequency
No HCP feedback
Low frequency
High frequency
General diabetes
education system
N/A
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1. Patients can view their data on a customizable graph.
2. Data were reviewed by an educator and all patients in the intervention arm were
sent a minimum of 1 personalized text-message communication per week for the first
6 months of the study.
1. Real-time graphical feedback on glucose levels.
2. The study team provided feedback on the blood glucose levels of patients, their
target goals, and their individualized medication regimens based on the data they
entered once a week or every 2 weeks.
3. Readings outside threshold limits would automatically trigger a message to be sent
to patients and notify clinicians.
4. Patients received an electronic action plan as pre-visit summaries for physician
office visits once a month.
1. Allows patients to use a number of charts and statistics that can visualize the
recorded information.
2. Data recorded can be made available to diabetes nurses.
1. Colour-coded graphical feedback on the data recorded was automatically displayed
following each data transfer.
2. MTH nurses provided feedback on out-of-range clinical readings (as needed).
3. MTH nurses made six weekly educational calls to deliver diabetes education.
4. MTH nurses supported insulin titration.
N/A
general diabetes
education system;
alerts for missed
readings and a
diabetes forum
Alerts and reminders,
a diabetes forum
N/A
$ Studies conducted on mixed populations of type 1 and type 2 diabetes patients
N/A No HCP feedback
Baron et al. (2016)
(34)$
Not specified BG, BP, physical activity, insulindose and weight
BG and BP data were
automatically
transmitted, other data
were manually entered
NO YES NO YES YES
When necessary plus
six weekly educational
calls
Low frequency
Drion et al. (2015)
(43) DBEES
BG, carbohydrate intake,
medication and physical exercise
Data were manually
entered NO NO NO YES NO
First 6 months:
approximately 2 text
messages per patient
per week; 5 minutes
per patient (n=36) per
week
High frequency
Zhou et al. (2016)
(32)$
Welltang
BG, carbohydrate intake,
medications, physical activity,
blood pressure, and weight/height
Data were manually
entered NO YES NO YES YES
Every one to two
weeks; average 3-10
min of time spent ;
mean number of
contacts was 11 (once
every week)
High frequency
Kirwan et al. (2013)
(42) Glucose Body
Blood glucose levels, insulin
dosages, other medications, diet
(food item in grams), and
physical activities (minutes)
Data were manually
entered NO NA NO YES YES
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Review question
The aim of this systematic review is to update the evidence of the effect of mobile phone applications (apps)
on glycemic control (HbA1c) in the self-management of diabetes and explore the factors that may influence
the efficacy of apps on glycemic control.
Searches
In the previous study, we searched relevant studies that were published between 1 January 1996 and 1 June
2015 from five databases: Medline, CINAHL, Cochrane Library, Web of Science, and Embase. For details of
the search strategy used, please refer to: "Do Mobile Phone Applications Improve Glycemic Control (HbA1c)
in the Self-management of Diabetes? A Systematic Review, Meta-analysis, and GRADE of 14 Randomized
Trials." Diabetes Care 39.11 (2016): 2089-2095. In this systematic review, we will update the searches in
Medline, CINAHL, Cochrane Library, Web of Science, and Embase databases to find relevant studies that
were published between 2015 and 2017. The search strategy used will be slightly modified to reflect some
research progress in this area. The following terms and medical subject headings (MeSH) were used during
the search: (mobile OR mHealth OR cellphone* OR MeSH “Cellular Phone” OR MeSH “Smartphone” OR
app OR apps OR phone* OR iphone* OR MeSH “Mobile Applications”) AND (MeSH “Diabetes Mellitus” OR
diabete* OR T2DM OR T1DM OR IDDM OR NIDDM OR DM OR T1D OR T2D OR MODY). The references
of the included studies will also be hand searched to identify any additional articles.
Types of study to be included
Only the studies that evaluated the effect of diabetes mobile phone apps on diabetes self-management and
adopted a randomised controlled trial (RCT) design will be included.
Condition or domain being studied
Diabetes mobile phone applications (diabetes apps) is a newly emerging technology for diabetes self-
management. Due to its ubiquitous, low-cost, interactive, and dynamic health promotion, there is potential for
diabetes apps to provide an effective intervention in diabetes self-care. Our previous systematic review with
GRADE of the evidence demonstrated that diabetes apps could help type 2 diabetes patients to control
HbA1c (Hou et al., 2016). This conclusion is also supported by a recent systematic review (Wu et al., 2017).
However, several questions still remain to be answered: 
1) Do diabetes apps improve glycemic control among type 1 diabetes patients? 
2) What functions of the apps are associated with better efficacy? 
3) Are there any other factors that may influence the effect of diabetes apps? 
                               Page: 1 / 6
Page 44 of 51
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
PROSPERO
International prospective register of systematic reviews
4) What is the evidence that using diabetes apps is safe for diabetes patients?
Participants/population
The participants were over 18 years old and had type 1 or type 2 diabetes. The self-management of
participants aged younger than 18 years largely relies on their parents. Therefore, studies with participants
age younger than 18 years were not included.
Intervention(s), exposure(s)
We define diabetes apps as mobile phone software that accepts data (transmitted or manual entry) and
provides feedback to patients on improved management (automated or by health care professional [HCP]).
Comparator(s)/control
The control group in the study received usual diabetes care without any telehealth program(s) linked to the
management of diabetes.
Context
Primary outcome(s)
The primary outcome of interest will be HbA1c.
Secondary outcome(s)
The secondary outcome will be severe hypoglycemia events reported. Studies included should report either
HbA1c as outcome or report hypoglycemia events in both intervention and control groups.
Data extraction (selection and coding)
Data will be extracted from each included study by one author (CH) and verified by a second author.
Disagreement will be resolved by discussion with a third author (BC or Jiayuan Li). The following data will be
extracted: author name, year of publish, study design, study length, setting, intervention group, control
group, number of participants randomised, number of participants withdrew, number of participants in the
analysis, imputation method, number of males and females, age, duration of diabetes, treatment regimen,
ethnic group, baseline HbA1c, post-intervention HbA1c, HbA1c change from baseline, hypoglycemia, app
used in the study, self-monitoring tasks supported, data entry method, and functions of the app (including
CHO/insulin bolus calculator, number of self-monitoring tasks supported, medication adjustment support,
structured feedback, target setting, reminders, HCP feedback, HCP feedback frequency and other
functionalities).
Risk of bias (quality) assessment
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Risk of bias will be independently evaluated by two authors using the Cochrane risk of bias tool and
discussed if needed by a third. Risk of bias will be assessed in the following domains: selection bias,
performance bias, detection bias (primary and secondary outcomes), attrition bias (primary and secondary
outcomes), reporting bias, and other bias (Higgins and Green, 2011). A third reviewer resolved any
discrepancies in bias coding. Studies will not be excluded on the basis of risk of bias. Studies will be
categorized as ‘low risk of bias’, high risk of bias, or ‘unclear’.
Strategy for data synthesis
Measure of treatment effect
For primary outcome, the treatment effect will be either mean difference in HbA1c or mean HbA1c at follow-
up, but mean difference in HbA1C is preferred.  
For secondary outcome, the treatment effect will be risk ratios (RR). 
Dealing with missing data
When required data is missing, we will first try to contact the corresponding authors of the studies. When
necessary, we will use specific statistical methods to calculate missing data (Ma et al., 2008).  
Meta-analysis
All the analyses will be conducted separately for type 1 and type 2 diabetes studies.
For primary outcome, pooling will be carried out using an inverse variance random effects model for type 1
and type 2 diabetes studies separately (DerSimonian and Laird, 1986). Heterogeneity will be assessed and
quantified using the I2 statistic. An I2 of 0% to 40% might represent no important heterogeneity, 30% to 60%
might represent moderate heterogeneity, 50% to 90% might represent substantial heterogeneity and 75% to
100% might represent considerable heterogeneity. When substantial heterogeneity is found (I2>50%), we
will try to explore the source of heterogeneity. 
For secondary outcome, pooling will be carried out using DerSimonian & Laird random effects model with the
estimate of heterogeneity being taken from the Mantel-Haenszel model (Mantel and Haenszel, 1959).
If studies were conducted on mixed participants with type 1 and type 2 diabetes, we will first contact the
corresponding authors of the studies for additional data. If additional data is not available, the studies will be
assigned to either type 1 or type 2 diabetes group according to the percentage of participants with type 1 and
2 diabetes. 
For studies with multiple intervention groups, only the intervention group that are relevant to meta-analysis
will be selected. If more than two groups are relevant, we will combine the groups to create a pair-wise
comparison.  
For cluster randomised controlled trial, effect size extracted from an analysis that properly accounts for the
cluster design is preferred. Otherwise, an effective sample size will be used instead: Neffective=
(k*m)/(1+(m-1)*ICC), where k indicates the number of clusters; m, the number of observations per cluster;
and ICC, the intracluster correlation coefficient.
Analysis of subgroups or subsets
Based on our previous study, a small number of type 1 diabetes studies is anticipated. Therefore, we will
only carry out few subgroup analyses on studies with type 1 diabetes to explore heterogeneity. The following
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subgroup analyses will be carried out: by length of the study follow up (less than one month, between one
and six months, and greater than 6 months), and by functions of the apps (with CHO/insulin bolus calculator
vs without CHO/insulin bolus calculator, with HCP feedback vs without HCP feedback).
For type 2 diabetes studies, univariate meta-regression will be conducted first by length of the study follow
up, baseline HbA1c level, age of the participants and medication regimen. Effects that found to be
statistically significant (p<0.1) will be included in the next multivariate meta-regression. A multivariable meta-
regression will then be conducted using restricted maximum likelihood (REML) random effect model (Van
Houwelingen et al., 2002). This model will be used to explore which functions of the apps (HCP feedback,
number of self-monitoring tasks supported, structured feedback, reminders, and data entry method) are
associated with better efficacy after adjusting for effects that found to be statistically significant in the
univariate meta-regression. I-squared –residual in the multivariate meta-regression will be calculated to
reflect residual heterogeneity. 
Meta-analyses and meta-regression will be conducted using the STATA (Version 14.0). 
Sensitivity analysis
For primary outcome, sensitivity analyses will be carried out by removing studies with high risk of bias,
changing the parameter ICC for cluster RCTs, changing the method of missing data imputation and removing
studies conducted on mixed participants. 
For secondary outcome, sensitivity analyses will be carried out by changing the statistical model to the
Mantel and Haenszel and the inverse variance fixed effect model (Higgins and Green, 2011).
Publication bias
A funnel plot will be used to visually inspect publication bias where 10 or more studies are pooled (Higgins
and Green, 2011).
Independent participant meta-analysis
Authors of all included studies will be contacted and asked to provide the individual data to carry out an
individual participant meta-analysis (Riley et al., 2010). The outcomes will be analysed as per the traditional
meta-analysis, however studies will be fitted as random effects and important and consistent covariates
included will include: patient age; gender, and group allocated. As per previous analyses, the analyses will
be carried out separately for type 1 and type 2 diabetes. All analyses will be carried out in Stata 14.
Contact details for further information
Prof. Jiayuan Li and Dr. Ben Carter
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was done at the study or outcome level), and how this information is to be used in any data synthesis. 
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Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). Page 7-8 
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Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). Page 11-13
DISCUSSION 
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